

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Environmental Research

journal homepage: [www.elsevier.com/locate/envres](http://www.elsevier.com/locate/envres)

# Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain

Narmeen Mallah<sup>a,b,c</sup>, Jacobo Pardo-Seco<sup>a,b,c</sup>, Luis-Ricardo López-Pérez<sup>d</sup>, Juan-Manuel González-Pérez<sup>d</sup>, Benigno Rosón<sup>d</sup>, María-Teresa Otero-Barrós<sup>e</sup>, Carmen Durán-Parrondo<sup>e</sup>, Victoria Nartallo-Penas<sup>f</sup>, Susana Mirás-Carballal<sup>g</sup>, Carmen Rodríguez-Tenreiro<sup>a,b,c</sup>, Irene Rivero-Calle<sup>a,b,c,h</sup>, Alberto Gómez-Carballa<sup>a,b,c</sup>, Antonio Salas<sup>a,b,c,i</sup>, Federico Martín-Torres<sup>a,b,c,h,\*</sup>

<sup>a</sup> Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), Galicia, Spain

<sup>b</sup> WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain

<sup>c</sup> Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

<sup>d</sup> Subdirección de Sistemas y Tecnologías de La Información, Servizo Galego de Saude, Galicia, Spain

<sup>e</sup> Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain

<sup>f</sup> Programa Gallego de Vacunación, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain

<sup>g</sup> Servicio de Enfermedades Transmisibles, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain

<sup>h</sup> Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and Universidad de Santiago de Compostela (USC), Galicia, Spain

<sup>i</sup> Unidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, And GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago, Servizo Galego de Saúde, Galicia, Spain

## ARTICLE INFO

### Keywords:

COVID-19 booster vaccine effectiveness  
Comorbidities  
Population-based study  
SARS-CoV-2  
Spain

## ABSTRACT

**Background:** Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data on vaccine effectiveness (VE) in comorbid patients are limited. We aimed to estimate booster dose VE against SARS-CoV-2 infection and COVID-19 severity in the general population and in comorbid patients.

**Method:** A retrospective test-negative control study was undertaken in Galicia-Spain (December 2020–November 2021). VE and 95% confidence interval (CI) were estimated using multivariate logistic regression models.

**Results:** 1,512,415 (94.13%) negative and 94,334 (5.87%) positive SARS-CoV-2 test results were included. A booster dose of COVID-19 vaccine is associated with substantially higher protection against SARS-CoV-2 infection than vaccination without a booster [VE<sub>boosted</sub> = 87% (95%CI: 83%; 89%); VE<sub>non-boosted</sub> = 66% (95%CI: 65%; 67%)]. The high VE was observed in all ages, but was more pronounced in subjects older than 65 years. VE against COVID-19 severity was analyzed in a mixed population of boosted and non-boosted individuals and considerable protection was obtained [VE: hospitalization = 72% (95%CI: 68%; 75%); intensive care unit administration = 83% (95%CI: 78%; 88%), in-hospital mortality = 66% (95%CI: 53%; 75%)]. Boosted comorbid patients are more protected against SARS-CoV-2 infection than those who were non-boosted. This was observed in a wide range of major diseases including cancer (81% versus 54%), chronic obstructive pulmonary disease (84% versus 61%), diabetes (84% versus 65%), hypertension (82% versus 65%) and obesity (91% versus 67%), among others.

**Conclusions:** A booster dose of COVID-19 vaccine increases the protection against SARS-CoV-2 infection and COVID-19 severity in the general population and in comorbid patients.

## 1. Introduction

Vaccination against Severe Acute Respiratory Syndrome Coronavirus

2 (SARS-CoV-2) remains the fundamental preventive measure against spreading the virus and developing severe Coronavirus Disease 2019 (COVID-19) disease, but whether a booster dose is necessary remains a

\* Corresponding author. Hospital Clínico Universitario de Santiago de Compostela, A Choupana s.n., 15701, Santiago de Compostela, Spain.

E-mail address: [federico.martinon.torres@usc.es](mailto:federico.martinon.torres@usc.es) (F. Martín-Torres).

<https://doi.org/10.1016/j.envres.2022.114252>

Received 18 June 2022; Received in revised form 22 August 2022; Accepted 30 August 2022

Available online 10 September 2022

0013-9351/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

point of debate (Shekhar et al., 2021). Studies on COVID-19 vaccine effectiveness (VE) suggested declining protection over time, yet no global consensus has been reached on the speed of this decrease (Feikin et al., 2022). A study in Israel reported that antibody titer reached the climax after one month of the second dose of BNT162b2, and then declined rapidly (Khoury et al., 2021). In their study, Naaber and colleagues documented that the antibody levels declined six months after the second dose of BNT162b2, revealing a decrease in the immune response over time (Naaber et al., 2021). A study in Northern California showed that mRNA-1273 VE against SARS-CoV-2 infection moderately decreased from 88% to 76% at 6–8 months after vaccination (Florea et al., 2022).

The impact of booster dose administration on COVID-19 is ongoing research. The World Health Organization (WHO), continues to review the emerging evidence on the need for and timing of a booster dose for the currently available COVID-19 vaccines (World Health Organization, 2021), but studies are still limited. Besides, the external validity of findings on VE is influenced by setting-specific parameters such as adherence to vaccine doses and time intervals for dose administration, access to healthcare, number of undertaken SARS-CoV-2 tests, the threshold for COVID-19 hospitalization and intensive care admission, as well as COVID-19 management strategy and the applied non-pharmaceutical interventions at different time points of the pandemic (e.g., lockdowns, facemasks, social distancing, etc.). Studies in different settings and populations would therefore aid in assessing the impact of booster administration.

Moreover, although it has been widely reported that comorbid patients are very likely to develop serious COVID-19 outcomes (CDC: Center for Disease Control and Prevention, 2019; He et al., 2022; Chiner-Vives et al., 2022; Gonzalez-Barcala et al., 2022; Adab et al., 2022; Ejaz et al., 2020), several vulnerable groups were not sufficiently included in clinical trials on COVID-19 vaccines. Therefore, the degree of protection offered by recall COVID-19 vaccine doses in individuals with medical conditions requires further investigation.

Spain was among the countries most affected by SARS-CoV-2 pandemic with 5,111,842 cases and 87,904 deaths as of November 24, 2021 (Ministerio de Sanidad Consumo y Bienestar Social [Ministry of Health Consumption and Social Welfare], 2021). It prioritized vaccination of inmates, social and healthcare workers and residents of long-term care facilities, front-line healthcare staff and elderly individuals to reduce the risk of COVID-19 related morbidity and mortality in these populations, and thereafter decrease the burden on public health facilities (Gobierno de España [Spanish Government], 2022). Vaccination of the other groups of the population was introduced successively following a priority order according to age, medical status, and occupation (Gobierno de España [Spanish Government], 2022).

Monge and colleagues reported a moderate VE of booster mRNA vaccine dose against SARS-CoV-2 infections; however, the study was limited to individuals older than 40 years and excluded individuals at risk of infection (Monge et al., 2022). Using real-world data of around 3,000,000 Polymerase Chain Reaction (PCR)-based SARS-CoV-2 tests, we extend the study of Monge by investigating the impact of a booster dose administration against SARS-CoV-2 infection as well as COVID-19 severe illness resulting in hospitalization, admission to intensive care unit (ICU), and death. We undertook a population-based study in Galicia, Northwest Spain that involved individuals older than 11 years and explored the impact of a booster dose on a large variety of comorbidities.

## 2. Methods

### 2.1. Settings

This study was initiated within the framework of a project on COVID-19 VE in Galicia, a region located in Northwest Spain (Pardo-Seco et al., 2022). Galicia is an autonomous community with a total inhabitants of 2,694,245 (Instituto Galego de Estatística, 2021a), for 29,576 km<sup>2</sup>

(Instituto Galego de Estatística, 2019) i.e., its population density is similar to that of the European population. The gender distribution in Galicia is 48% (N = 1,296,602) males and 52% (N = 1,397,643) females. Almost 9% of the Galician population are aged 80 and above (N = 236,788), 17% are in the age range of 65–79 (N = 457,245), 22% are aged between 50 and 64 (N = 596,034), while the rest are younger adults and children (Instituto Galego de Estatística, 2021b).

The Galician Healthcare Service (SERGAS) is a public health system with universal access to healthcare at low or no cost. Galicia has 6,571 public hospital beds distributed in 35 hospitals (data of 2020) (Instituto Galego de Estatística, 2020). COVID-19 vaccine has been made freely available for all the population, and it was administered by priority order according to occupation, age, and medical status (Gobierno de España [Spanish Government], 2022). During the study period (December 26, 2020–November 23, 2021), the following four vaccines were administered in Spain: Pfizer-BioNTech vaccine (BNT162b2), Vaxzevria (ChAdOx1 nCoV-19), Spikevax (mRNA-1273), and Janssen (Ad26. COV2-S) (European Medicines Agency, 2022). A full vaccine course of BNT162b2, mRNA-1273, or ChAdOx1 nCoV-19 consisted of two injections with a predefined time separation between the first and the second injection, while Ad26. COV2-S was given as a single injection. Until the start of the study, the vaccination campaign encompassed individuals 11 years or above, hence, those younger than that age were excluded from the study.

### 2.2. Ethics

The study did not involve an intervention or the use of human biological samples. SERGAS provided the authors with anonymized data, waiving the need for written informed consent. SERGAS did not take part in data analysis. The study protocol was approved by the clinical research ethics committee of Galicia (CEIC, protocol number: 2022–175).

### 2.3. Study design

A retrospective test-negative case-control study was conducted to determine the effectiveness of COVID-19 vaccines administered in Galicia-Spain, against SARS-CoV-2 infection as well as against severe COVID-19 causing hospitalization, ICU admission, or death.

To estimate VE in fully susceptible people, we excluded from the analysis those individuals who had a previous positive SARS-CoV-2 PCR, antigen or antibody test result at any time before the enrolment date in the study. Antibody response to the vaccine in infection-naive individuals takes more time than in those who had been infected with the virus in the past (Tut et al., 2021).

A positive SARS-CoV-2 PCR test result represented a case, while a negative test result was deemed a control. An individual could contribute to the study by one or more negative tests; however, only one positive SARS-CoV-2 PCR test was considered per patient. During the study period, SARS-CoV-2 PCR test results were performed at no cost by SERGAS health centers for clinical motives such as presenting COVID-19-related symptoms or being in close contact with a SARS-CoV-2 infected individual in the last two weeks.

### 2.4. Exposure definition

In our settings, the exposure was defined as receiving any injection of COVID-19 vaccine. Individuals were categorized into unvaccinated, partially vaccinated, non-boosted and boosted according to their exposure status, in order to focus on SARS-CoV-2 infection acquired since vaccination after a sufficient interval for biological protection. Unvaccinated individuals are those who did not receive any COVID-19 vaccine injection during the study period. Partially vaccinated individuals are those who received a single dose of BNT162b2, mRNA-1273 or ChAdOx1 nCoV-19, as well as those who were given the two injections of

these vaccines or the single injection of Ad26. COV2–S, but with less than seven days after the last injection. Non-booster individuals are those who received the complete course of the vaccine counting since the 7th day after the last injection. Booster individuals are those who received an additional dose of the vaccine counting at least seven days after the injection.

2.5. Outcome definition

The primary outcome of the study consisted of SARS-CoV-2 infection confirmed by a PCR-based test. The date of SARS-CoV-2 infection was considered the date of the first positive PCR test.

Secondary outcomes included hospitalization, ICU admission, or mortality attributed to severe COVID-19. Only in-hospital death events were considered for the mortality analysis.

SARS-CoV-2 was deemed a cause of hospitalization if a patient had a positive PCR test result in the 30 days preceding the hospital admission or within three days after hospitalization (Yeo et al., 2021; Mehta et al., 2021). To account for nosocomial infections, patients with a positive SARS-CoV-2 PCR test after three days of hospitalization were not included in the analysis. ICU admissions and in-hospital mortality were ascertained among the population of COVID-19 hospitalized patients.

2.6. Statistical analysis

Adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were estimated using multivariate logistic regression models. Unvaccinated individuals were used as a reference. The models were directly adjusted for age and sex due to their biological plausibility, and other variables were added to control confounding. To account for socioeconomic differences the following three variables were used as a proxy of this indicator: 1) sanitary area which represents the area of residence; 2) pharmaceutical cost contribution defined as the percentage of medicine cost paid by the participants according to their income tax; and 3) receiving social support. Data on comorbidities associated with each individual were also collected. The comorbidities included: atrial fibrillation, cancer, chronic obstructive pulmonary disease (COPD),

dementia, depression, diabetes, epilepsy, heart failure, human immunodeficiency virus (HIV), hypertension, ischemic cardio-pathology, kidney failure, obesity, stroke, and Parkinson disease. Information on receiving any of pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, or flu vaccine was also retrieved. The evolution of the epidemiological situation of the pandemic was considered by computing the time period between the PCR test date and the COVID-19 vaccination date. We examined the effect of each potentially confounding variable using the change-in-estimate method. For this purpose, a univariate analysis was performed and the covariables with a p-value <0.2 were consecutively added to the model (Greenland, 1989). A covariable was kept in the model if it changed the originally estimated OR by at least 10%. The effectiveness of COVID-19 vaccination status was then calculated as follows:  $VE = (1 - OR_{adjusted}) \times 100$ . When the number of observations to estimate the effectiveness of the booster against a certain outcome was not sufficient, a mixed population of booster and non-booster individuals was used.

The analysis was stratified by age group and comorbidities.

All analyses were undertaken using STATA v.12 (Stata Statistical Software: Release 12; StataCorp LP; College Station, TX, USA).

3. Results

Fig. 1 summarizes how the sample size of the analysis was reached. A total of 909,636 individuals fulfilled the inclusion criteria and contributed 1,606,749 SARS-CoV-2 test results to the analysis. Among the included individuals, 94,334 were infected with SARS-CoV-2, whereas the remaining 815,302 individuals were negative for SARS-CoV-2. The number of SARS-CoV-2 infected individuals was the same as that of the positive SARS-CoV-2 test results (94,334; 5.87% of total PCR tests) as only one SARS-CoV-2 PCR positive test was considered per individual. The 815,302 SARS-CoV-2 negative people, provided 1,512,415 (94.13% of total PCR tests) test results to the analysis since each individual could contribute one or more negative SARS-CoV-2 PCR test results to the study. The analysis unit in our study is the test, not the person. Fig. 2 represents the distribution of the negative tests across the study population. Of the negatively tested individuals, 58.2% contributed only one




Fig. 1. Flow diagram of participants and SARS-COV-2 PCR test results entry the study.




Fig. 2. Distribution of SARS-CoV-2 PCR negative test results per individual.

negative test result, 25.4% provided two negative test results, 16.4% shared more than two negative test results, and 2.5% gave more than 5 negative test results (Fig. 2).

In 1,155 infected individuals, COVID-19 was not deemed the cause of hospitalization as SARS-CoV-2 infection was either nosocomial or the hospitalization took place more than 30 days after infection. Accordingly, 93,179 infected individuals were included in the analysis of VE against COVID-19 hospitalization, ICU admission and in-hospital mortality. Of the 93,179 infected individuals, 5,871 (6.30%) were hospitalized for COVID-19, and 925 (0.99%) were further admitted to ICU. One thousand and eight (1.08%) in-hospital deaths for COVID-19 were also registered.

The general and clinical characteristics of the study population are presented in Table 1.

Impact of COVID-19 booster-based vaccination on SARS-CoV-2 infection and COVID-19 severity.

Receiving a booster dose of COVID-19 vaccine increased the protection against infection by SARS-CoV-2 from 66% in non-boostered individuals to 87% [ $VE_{\text{non-boostered}} = 66\%$  (95%CI: 65%; 67%);  $VE_{\text{boostered}} = 87\%$  (95%CI: 83%; 89%)] (Table 2).

Only four (0.07%) boostered individuals who had been tested positive for SARS-CoV-2 were hospitalized for COVID-19. VE against COVID-19 hospitalization was then estimated in the mixed subpopulation of non-boostered and boostered individuals and a protection exceeding 70% was observed [ $VE = 72\%$  (95%CI: 68%; 75%)] (Table 3).

None of those individuals who tested positive for SARS-CoV-2 and had received a booster dose of the vaccine was admitted to ICU or died for COVID-19, thus VE against these outcomes was estimated in the mixed subpopulation of non-boostered and boostered individuals. VE against ICU admission was 83% (95%CI: 78%; 88%), and that against in-hospital mortality was 66% (95%CI: 53%; 75%).

In our study population, only mRNA type vaccines were administered as a booster. Restricted analysis of individuals who had received mRNA-type vaccines exclusively, showed 88% VE against SARS-CoV-2 infections [ $VE = 88\%$  (95%CI: 85%; 90%)]. Among individuals who had received the mRNA booster dose, only four were hospitalized and none was admitted to ICU or died of COVID-19. In a mixed subpopulation of non-boostered and boostered individuals, VE against hospitalization for COVID-19 was 74% (95%CI: 70%; 77%); ICU admission 86% (95%CI: 80%; 90%) and in-hospital mortality 71% (95%CI: 59%; 79%) (Table S2).

Impact of COVID-19 booster-based vaccination on SARS-CoV-2 infection and COVID-19 severity stratified by age.

When stratifying the study population by age, sufficient observations of boostered individuals were only obtained for those older than 65 years. Receiving a booster dose of the COVID-19 vaccine offers more than 80% protection against SARS-CoV-2 infection in the elderly population [66–80 years:  $VE = 85\%$  (95%CI: 77%; 91%);  $\geq 81$  years:  $VE = 82\%$  (95%CI: 75%; 87%)] (Table 2). For the younger age categories, VE was estimated in the mixed subpopulation of non-boostered and boostered individuals due to insufficient number of observations, and ranged between 51% and 76% (Table 2).

Likewise, the effectiveness of receiving a booster dose of COVID-19 vaccine against hospitalization was more than 70% in people aged over 65 years [66–80 years:  $VE = 71\%$  (95%CI: 62%; 78%);  $\geq 81$  years:  $VE = 73\%$  (95%CI: 64%; 80%)] (Table 3). VE against hospitalization in the younger age groups ( $\geq 18$  years) was estimated in the mixed subpopulation of non-boostered and boostered individuals and ranged between 69% and 84% (Table 2).

Comparing the mixed subpopulation of non-boostered and boostered individuals to unvaccinated individuals showed a substantial VE against ICU admission for COVID-19 in individuals aged between 46 and 65 years [ $VE = 86\%$  (95%CI: 77%; 91%)] and in those older than 65 years [ $VE = 83\%$  (95%CI: 73%; 89%)]. The data also revealed considerable protection against death for COVID-19 in individuals older than 65 years [ $VE = 65\%$  (95%CI: 50%; 75%)].

Impact of COVID-19 booster-based vaccination on SARS-CoV-2 infection and COVID-19 severity stratified by comorbidity type.

Individuals with any of the following comorbidities and who received a booster dose of COVID-19 vaccine are more protected against SARS-CoV-2 infection than those who were non-boostered: cancer [ $VE_{\text{non-boostered}} = 54\%$  (95%CI: 49%; 59%);  $VE_{\text{boostered}} = 81\%$  (95%CI: 68%; 88%)], COPD [ $VE_{\text{non-boostered}} = 61\%$  (95%CI: 55%; 67%);  $VE_{\text{boostered}} = 84\%$  (95%CI: 66%; 93%)], depression [ $VE_{\text{non-boostered}} = 62\%$  (95%CI: 59%; 65%);  $VE_{\text{boostered}} = 83\%$  (95%CI: 74%; 89%)], diabetes [ $VE_{\text{non-boostered}} = 65\%$  (95%CI: 62%; 68%);  $VE_{\text{boostered}} = 84\%$  (95%CI: 75%; 90%)], hypertension [ $VE_{\text{non-boostered}} = 65\%$  (95%CI: 63%; 68%);  $VE_{\text{boostered}} = 82\%$  (95%CI: 76%; 86%)], ischemic heart disease [ $VE_{\text{non-boostered}} = 56\%$  (95%CI: 49%; 63%);  $VE_{\text{boostered}} = 79\%$  (95%CI: 60%; 90%)], kidney failure [ $VE_{\text{non-boostered}} = 67\%$  (95%CI: 61%; 72%);  $VE_{\text{boostered}} = 85\%$  (95%CI: 70%; 92%)], obesity [ $VE_{\text{non-boostered}} = 67\%$  (95%CI: 65%; 69%);  $VE_{\text{boostered}} = 91\%$  (95%CI: 83%; 95%)], and stroke [ $VE_{\text{non-boostered}} = 66\%$  (95%CI: 60%; 71%);  $VE_{\text{boostered}} = 85\%$  (95%CI: 68%; 93%)] (Table 4).

Few individuals with epilepsy or Parkinson who had received the booster dose of COVID-19 vaccine tested positive for SARS-CoV-2, therefore VE against infection in these subgroups was estimated in the mixed population of non-boostered and boostered individuals. Substantial protection against SARS-CoV-2 infection was observed for epilepsy [ $VE = 66\%$  (95%CI: 58%; 73%)] and Parkinson patients [ $VE = 74\%$  (95%CI: 64%; 81%)] (Table 4).

Few patients with comorbidity who had received the booster dose of the COVID-19 vaccine were hospitalized for COVID-19, hence VE against hospitalization was estimated by comparing the odds of hospitalization in the mixed population to that of unvaccinated individuals. Vaccinated comorbid patients showed lower odds of COVID-19 related hospitalization than unvaccinated ones. VE ranged between 49% and 79% (Table 5).

VE against ICU admission for COVID-19 was estimated in the mixed population of non-boostered and boostered individuals relative to unvaccinated people. Significant protection against COVID-19-related ICU admission was observed in patients with cancer [ $VE = 87\%$  (95%CI: 71%; 94%)], depression [ $VE = 87\%$  (95%CI: 73%; 94%)], diabetes [ $VE = 83\%$  (95%CI: 70%; 91%)], hypertension [ $VE = 83\%$  (95%CI: 72%; 89%)], and obesity [ $VE = 84\%$  (95%CI: 73%; 91%)]. VE against COVID-19-related ICU admission could not be estimated for other comorbid groups due to the limited number of observations.

**Table 1**

Sociodemographic and clinical characteristics of the study population per each of the outcomes: infection with SARS-CoV-2; hospitalization for COVID-19; intensive care unit (ICU) admission for COVID-19; and in-hospital death for COVID-19.

Characteristic	Infection N (%)			Hospitalization N (%)			ICU Admission N (%)			In-hospital Death N (%)		
	No	Yes	Total	No	Yes	Total	No	Yes	Total	No	Yes	Total
<b>N (%)</b>	1,512,415 (94.13)	94,334 (5.87)	1,606,749 (100)	87,308 (93.70)	5871 (6.30)	93,179 (100)	92,254 (99.01)	925 (0.99)	93,179 (100)	92,340 (98.92)	1008 (1.08)	93,348 (100)
<b>Age (years)</b>												
Mean (SD)	49.40 (21.68)	42.63 (21.10)	45.0 (21.70)	40.82 (20.20)	64.28 (19.24)	42.30 (20.93)	42.12 (20.91)	60.05 (14.0)	42.30 (20.93)	41.93 (20.65)	81.75 (10.61)	42.36 (20.98)
Range	11–111	11–107	11–111	11–107	11–102	11–107	11–107	13–94	11–107	11–107	29–104	11–107
<b>Age quartiles†</b>												
1st quartile: 11 - 32	375,231 (24.81)	35,850 (38.00)	411,081 (25.58)	35,354 (40.49)	438 (7.46)	35,792 (38.41)	35,750 (38.75)	42 (4.54)	35,792 (38.41)	35,791 (38.76)	1 (0.10)	35,792 (38.34)
2nd quartile: 33 - 48	392,178 (25.93)	23,334 (24.74)	415,512 (25.86)	22,397 (25.65)	844 (14.38)	23,241 (24.94)	23,093 (25.03)	148 (16.00)	23,241 (24.94)	23,234 (25.16)	7 (0.69)	23,241 (24.90)
3rd quartile: 49 - 65	373,152 (24.67)	19,874 (21.07)	393,026 (24.46)	18,096 (20.73)	1524 (25.96)	19,620 (21.06)	19,266 (20.88)	354 (38.27)	19,620 (21.06)	19,556 (21.18)	84 (8.33)	19,640 (21.04)
4th quartile: 66 - 111	371,854 (24.59)	15,276 (16.19)	387,130 (24.09)	11,461 (13.13)	3065 (52.21)	14,526 (15.59)	14,145 (15.33)	381 (41.19)	14,526 (15.59)	13,759 (14.90)	916 (90.87)	14,675 (15.72)
<b>Gender**†</b>												
Male	672,291 (44.45)	45,229 (47.95)	717,520 (55.34)	41,398 (47.42)	3194 (54.40)	44,592 (47.86)	43,969 (47.66)	623 (67.35)	44,592 (47.86)	44,139 (47.80)	554 (54.96)	44,693 (47.88)
Female	840,124 (55.55)	49,105 (52.05)	889,229 (55.34)	45,910 (52.58)	2677 (45.60)	48,587 (52.14)	48,285 (52.34)	302 (32.65)	48,587 (52.14)	48,201 (52.20)	454 (45.04)	48,655 (52.12)
<b>COVID-19 vaccine**‡</b>												
Unvaccinated	917,498 (60.66)	69,816 (74.01)	987,314 (61.45)	64,251 (73.59)	4609 (78.50)	68,860 (73.90)	68,067 (73.78)	793 (85.73)	68,860 (73.90)	68,279 (73.94)	730 (72.42)	69,009 (73.93)
Partially vaccinated	158,103 (10.45)	8937 (9.47)	167,040 (10.40)	8459 (9.69)	431 (7.34)	8890 (9.54)	8843 (9.98)	47 (5.08)	8890 (9.54)	8770 (9.50)	124 (12.30)	8894 (9.53)
Fully vaccinated	428,756 (28.35)	15,498 (16.43)	444,254 (27.65)	14,522 (16.63)	827 (14.09)	15,349 (16.47)	15,264 (16.55)	85 (9.19)	15,349 (16.47)	15,211 (16.47)	154 (15.28)	15,365 (16.46)
Fully vaccinated and booster	8058 (0.53)	83 (0.09)	8141 (0.51)	76 (0.09)	4 (0.07)	80 (0.09)	80 (0.09)	0 (0.00)	80 (0.09)	80 (0.09)	0 (0.00)	80 (0.09)
<b>Flu vaccine**†</b>												
Vaccinated	661,912 (43.77)	29,005 (30.75)	690,917 (43.00)	24,830 (28.44)	3396 (57.84)	28,226 (30.29)	27,740 (30.07)	486 (52.54)	28,226 (30.29)	27,251 (29.80)	836 (82.94)	28,357 (30.38)
Unvaccinated	850,503 (56.23)	65,329 (69.25)	915,832 (57.00)	62,478 (71.56)	2475 (42.16)	64,953 (69.71)	64,514 (69.93)	439 (47.46)	64,953 (69.71)	64,819 (70.20)	172 (17.06)	64,991 (69.62)
<b>Pneumococcal conjugate vaccine**‡,†</b>												
Vaccinated	165,174 (10.92)	9207 (9.76)	174,381 (10.85)	8416 (9.64)	631 (10.75)	9047 (9.71)	8933 (9.68)	114 (12.32)	9047 (9.71)	8868 (9.60)	200 (19.84)	9068 (9.71)
Unvaccinated	1,347,241 (89.08)	85,127 (90.24)	1,432,368 (89.15)	78,892 (90.36)	5240 (89.25)	84,132 (90.29)	83,321 (90.32)	811 (87.68)	84,132 (90.29)	83,472 (90.40)	808 (80.16)	84,280 (90.29)
<b>Pneumococcal polysaccharide vaccine**†</b>												
Vaccinated	178,026 (11.77)	7008 (7.43)	185,034 (11.52)	5404 (6.19)	1286 (21.90)	6690 (7.18)	6484 (7.03)	206 (22.27)	6690 (7.18)	6419 (6.95)	321 (31.85)	6740 (7.22)
Unvaccinated	1,334,389 (88.23)	87,326 (92.57)	1,421,715 (88.48)	81,904 (93.81)	4585 (78.10)	86,489 (92.82)	85,770 (92.97)	719 (77.73)	86,489 (92.82)	85,921 (93.05)	687 (68.15)	86,608 (92.78)
<b>Presence of comorbidities (yes)</b>												
Obesity**†	236,286 (15.62)	12,737 (13.50)	249,023 (15.50)	10,515 (12.04)	1829 (31.15)	12,344 (13.25)	11,960 (12.96)	384 (41.51)	12,344 (13.25)	12,108 (13.11)	287 (28.47)	12,395 (13.28)
Depression**†	204,577 (13.53)	8270 (8.77)	212,847 (13.25)	6839 (7.83)	1156 (19.69)	7995 (8.58)	7849 (8.51)	146 (15.78)	7995 (8.58)	7826 (8.48)	204 (20.24)	8030 (8.60)
Diabetes**†	168,868 (11.17)	7115 (7.54)	175,983 (10.95)	5274 (6.04)	1488 (25.34)	6762 (7.26)	6510 (7.06)	252 (27.24)	6762 (7.26)	6490 (7.03)	344 (34.13)	6834 (7.32)
COPD**†	75,539 (4.99)	2366 (2.51)	77,905 (4.85)	1562 (1.79)	637 (10.85)	2199 (2.36)	2125 (2.30)	74 (8.00)	2199 (2.36)	2064 (2.24)	161 (15.97)	2225 (2.38)
Atrial fibrillation**†	89,838 (5.94)	2906 (3.08)	92,744 (5.77)	1825 (2.09)	827 (14.09)	2652 (2.85)	2559 (2.77)	93 (10.05)	2652 (2.85)	2397 (2.60)	317 (31.45)	2714 (2.91)
Hypertension**†	390,812 (25.84)	16,672 (17.67)	407,484 (25.36)	12,959 (14.84)	2980 (50.76)	15,939 (17.11)	15,479 (16.78)	460 (49.73)	15,939 (17.11)	15,342 (16.61)	734 (72.82)	16,076 (17.22)
Heart failure**†	81,349 (5.38)	2191 (2.32)	83,540 (5.20)	1173 (1.34)	756 (12.88)	1929 (2.07)	1878 (2.04)	51 (5.51)	1929 (2.07)	1659 (1.80)	332 (32.94)	1991 (2.13)
Kidney failure**†	79,955 (5.29)	2185 (2.32)	82,140 (5.11)	1247 (1.43)	728 (12.40)	1975 (2.12)	1896 (2.06)	79 (8.54)	1975 (2.12)	1739 (1.88)	293 (29.07)	2032 (2.18)
Cancer**†	159,940 (10.58)	5289 (5.61)	165,229 (10.28)	4120 (4.72)	895 (15.24)	5015 (5.38)	4120 (4.72)	895 (15.24)	5015 (5.38)	4799 (5.20)	270 (26.79)	5069 (5.43)
Ischemic cardio-pathology**†	73,100 (4.83)	2585 (2.74)	75,685 (4.71)	1785 (2.04)	617 (10.51)	2402 (2.58)	2310 (2.50)	92 (9.95)	2402 (2.58)	2244 (2.43)	203 (20.14)	2447 (2.62)
Stroke**†	65,833 (4.35)	2075 (2.20)	67,908 (4.23)	1431 (1.64)	493 (8.40)	1924 (2.06)	1866 (2.02)	58 (6.27)	1924 (2.06)	1775 (1.92)	198 (19.64)	1973 (2.11)
Epilepsy**†	23,544 (1.56)	963 (1.02)	24,507 (1.53)	778 (0.89)	141 (2.40)	919 (0.99)	901 (0.98)	18 (1.95)	919 (0.99)	889 (0.96)	39 (3.87)	928 (0.99)
Dementia**†	55,383 (3.66)	1859 (1.97)	57,242 (3.56)	1250 (1.43)	490 (8.35)	1740 (1.87)	1736 (1.88)	4 (0.43)	1740 (1.87)	1517 (1.64)	250 (24.80)	1767 (1.89)

(continued on next page)

Table 1 (continued)

Characteristic	Infection N (%)			Hospitalization N (%)			ICU Admission N (%)			In-hospital Death N (%)		
	No	Yes	Total	No	Yes	Total	No	Yes	Total	No	Yes	Total
Parkinson disease <sup>†</sup>	15,017 (0.99)	463 (0.49)	15,480 (0.96)	289 (0.33)	132 (0.25)	421 (0.45)	413 (0.45)		421 (0.45)	366 (0.40)	64 (6.35)	430 (0.46)
HIV	4339 (0.29)	143 (0.15)	4482 (0.28)	127 (0.15)	14 (0.24)	141 (0.15)	140 (0.15)	1 (0.11)	141 (0.15)	141 (0.15)	0 (0.00)	141 (0.15)
Multi-medicated (yes) <sup>*†</sup>	57,037 (3.77)	1741 (1.85)	58,788 (3.66)	1161 (1.33)	458 (7.80)	1619 (1.74)	1569 (1.70)	50 (5.41)	1619 (1.74)	1495 (1.62)	150 (14.88)	1645 (1.76)
<b>Proxy of socioeconomic status</b>												
<b>Receiving social protection<sup>*†</sup></b>												
No	1,465,683 (96.91)	92,883 (98.46)	1,558,566 (97.00)	86,303 (98.85)	5521 (94.04)	91,824 (98.55)	90,933 (98.57)	891 (96.32)	91,824 (98.55)	91,058 (98.61)	921 (91.37)	91,979 (98.53)
Yes	46,732 (3.09)	1451 (1.54)	48,183 (3.00)	1005 (1.15)	350 (5.96)	1355 (1.45)	1321 (1.43)	34 (3.68)	1355 (1.45)	1282 (1.39)	87 (8.63)	1396 (1.47)
<b>Contribution to paying medicine costs according to income<sup>*‡</sup></b>												
50%–60% of medicine cost	275,993 (19.21)	20,257 (22.25)	296,250 (19.39)	19,649 (23.02)	550 (11.36)	20,199 (22.39)	20,082 (22.45)	117 (15.92)	20,199 (22.39)	20,195 (22.39)	4 (33.33)	20,199 (22.39)
30%–40% of medicine cost	634,009 (44.13)	45,661 (50.15)	679,670 (44.49)	44,081 (51.64)	1410 (29.12)	45,491 (50.43)	25,274 (50.60)	217 (29.52)	45,491 (50.43)	45,490 (50.44)	1 (8.33)	45,491 (50.43)
10% of medicine cost	247,385 (17.22)	10,997 (12.08)	258,382 (16.91)	9138 (10.71)	1507 (31.12)	10,645 (11.80)	10,414 (11.64)	231 (31.43)	10,645 (11.80)	10,640 (11.80)	5 (41.67)	10,645 (11.80)
0% of medicine cost	279,206 (19.44)	14,140 (15.53)	293,346 (19.20)	12,493 (14.64)	1375 (28.40)	13,868 (15.37)	13,698 (15.31)	170 (23.13)	13,868 (15.37)	13,866 (15.37)	2 (16.67)	13,868 (15.37)
Unknown or missing	75,822 (5.00)	3279 (3.50)	79,101 (4.90)	1947 (2.20)	1029 (17.5)	2976 (3.20)	2786 (3.00)	190 (20.50)	2976 (3.20)	2149 (2.30)	12 (1.20)	3145 (3.40)

N: the number of PCR tests; ICU: intensive care unit; Hospitalization, ICU, and in-hospital death were determined in the subpopulation of SARS-CoV-2 positive PCR tests.

All variables listed in Table 1 showed a statistically significant association with SARS-CoV-2 infection ( $X^2$  p-value <0.001). They also showed a statistically significant association with hospitalization for COVID-19 ( $X^2$  p-value of Pneumococcal conjugate vaccine = 0.005;  $X^2$  p-value of the other variables <0.001), except HIV (p-value = 0.076).

$X^2$  p-value of the association with ICU admission for COVID-19 > 0.05.

$X^2$  p-value of the association with ICU admission for COVID-19 > 0.05.

\* :  $X^2$  p-value of the association with ICU admission for COVID-19 < 0.001.

\*\* :  $X^2$  p-value of the association with ICU admission for COVID-19 < 0.005. Variables without any asterisk showed.

†  $X^2$  p-value of the association with in-hospital death for COVID-19 < 0.001.

‡  $X^2$  p-value of the association with in-hospital death for COVID-19 < 0.005. Variables without any dagger showed.

#### 4. Discussion

The present population-based study showed high effectiveness of a third-dose booster schedule in preventing SARS-CoV-2 infection in Galicia-Spain. We reported that people who received a booster dose of COVID-19 vaccine are substantially more protected against SARS-CoV-2 infection than non-boostered individuals who had received any of the authorized vaccines but not the booster dose (VE = 87% versus VE = 66%). Our data support the utility of a booster dose of COVID-19 vaccine in developed country settings such as that of Spain in both age and comorbidity-based indications.

During our study period, most individuals who had received the booster dose were older than 65 years as this age range represents a priority group for vaccination in Spain. Upon stratification by age, elevated VE (>80%) from a booster dose against SARS-CoV-2 infection was maintained in people aged 66–80 years, as well as those 81 years and above. As for the younger age categories, VE was estimated in a mixed subpopulation of non-boostered and boostered individuals due to insufficient number of observations among individuals with a booster dose, and a protection against infection ranging between 51% and 76% was observed. We also showed that administering a booster dose is also associated with an important decrease in the likelihood of hospitalization for COVID-19 among people over 65 years (VE >70%). VE against ICU admission and in-hospital mortality was evaluated in the mixed vaccinated population of non-boostered and boostered individuals due to lack of observations among the boostered group. Vaccination against COVID-19 contributed to lowering the odds of ICU admission for COVID-19 by more than 80% in people aged between 46 and 65 years as well as in those older than 65 years. It also revealed 65% protection against death for COVID-19 in individuals older than 65 years.

Studies on the impact of administering a booster dose are emerging

and our findings are comparable to reports available so far. A study in Chile showed that a three-dose schedule prevents infection with SARS-CoV-2 between 79% and 97%, depending on the vaccine type (Jara et al., 2022). The study also reported considerable VE that ranged between 86% and 99% against hospitalization, ICU admission and death in individuals who received a booster dose (Jara et al., 2022). A preliminary study in Israel, reported 86% reduction in the odds of testing positive for SARS-CoV-2 in individuals who received a booster dose of BNT162b2 relative to those who received only two doses of the vaccine (Patalon et al., 2022). A second study in Israel also demonstrated that the rates of SARS-CoV-2 infection and COVID-19 related hospitalization was lower in the boostered group than those in the non-boostered group by factors of 11.3 and 19.5, respectively (Bar-On et al., 2021). Arbel and colleagues showed that the COVID-19-related mortality rate is 90% lower in Israeli people with a booster dose of BNT162b2 (Arbel et al., 2021). Barda et al. evaluated the effectiveness of a booster dose of BNT162b2 in Israel and estimated VE of 93% against COVID-19-related hospitalization and 81% against COVID-19-related death (Barda et al., 2021). A study in England reported that the effectiveness of a booster dose against symptomatic COVID-19 ranged from 94% to 97% and was similar in all age groups, and that against hospitalization or death oscillated between 97% and 99% in all age groups (Andrews et al., 2022). In the United States, VE against COVID-19-associated hospitalization was at least 90% among persons who had received a third dose of mRNA vaccine ≥14 days earlier (Thompson et al., 2022). In Spain, to the best of our knowledge, this is the first report on the effectiveness of the booster dose of COVID-19 vaccine.

As several particularly vulnerable groups were not included in sufficient numbers in clinical trials on COVID-19 vaccines, quantifying real-world VE, including both biological and behavioral effects is essential. In the present study, we found that administering a booster dose in

**Table 2**  
Vaccine effectiveness (VE) against SARS-CoV-2 infection.

Covid-19 vaccination	Infection		VE* (95%CI); p-value
	No N (%)	Yes N (%)	
<b>≥ 11 years</b>			
Unvaccinated	917,498 (60.66)	69,816 (74.01)	Reference
Partially vaccinated	158,103 (10.45)	8937 (9.47)	36% (35%; 38%); p-value <0.0001
Non-boosted	428,756 (28.35)	15,498 (16.43)	66% (65%; 67%); p-value <0.0001
Boosted	8058 (0.53)	83 (0.09)	87% (83%; 89%); p-value <0.0001
<b>11–17 years</b>			
Unvaccinated	99,133 (91.70)	9997 (92.68)	Reference
Partially vaccinated	4516 (4.18)	705 (6.54)	1% (–9%, 9%); p-value = 0.849
Non-boosted/boosted	4454 (4.12)	85 (0.79)	76% (69%; 82%); p-value <0.0001
<b>18–30 years</b>			
Unvaccinated	180,126 (78.11)	18,785 (83.98)	Reference
Partially vaccinated	21,694 (9.41)	2503 (11.19)	23% (19%; 26%); p-value <0.0001
Non-boosted/boosted	28,781 (12.48)	1080 (4.83)	69% (67%; 71%); p-value <0.0001
<b>31–45 years</b>			
Unvaccinated	243,684 (69.21)	15,082 (70.59)	Reference
Partially vaccinated	35,834 (10.18)	2924 (13.69)	8% (3%; 12%); p-value <0.0001
Non-boosted/boosted	72,552 (20.61)	3359 (15.72)	52% (50%; 54%); p-value <0.0001
<b>46–55 years</b>			
Unvaccinated	145,184 (59.23)	9432 (66.46)	Reference
Partially vaccinated	25,117 (10.25)	718 (5.06)	64% (61%; 67%); p-value <0.0001
Non-boosted/boosted	74,801 (30.52)	4043 (28.49)	51% (48%; 55%); p-value <0.0001
<b>56–65 years</b>			
Unvaccinated	111,703 (54.57)	6805 (65.78)	Reference
Partially vaccinated	30,547 (14.92)	867 (8.38)	53% (49%; 57%); p-value <0.0001
Non-boosted/boosted	62,435 (30.50)	2673 (25.84)	51% (47%; 53%); p-value <0.0001
<b>66–80 years</b>			
Unvaccinated	94,054 (43.75)	6474 (65.82)	Reference
Partially vaccinated	21,520 (10.01)	606 (6.16)	41% (35%; 46%); p-value <0.0001
Non-boosted	97,155 (45.20)	2735 (27.81)	67% (64%; 70%); p-value <0.0001
Boosted	2228 (1.04)	21 (0.21)	85% (77%; 91%); p-value <0.0001
<b>≥ 81 years</b>			
Unvaccinated	43,614 (27.80)	3241 (59.58)	Reference
Partially vaccinated	18,875 (12.03)	614 (11.29)	48% (43%; 53%); p-value <0.0001
Non-boosted	90,037 (57.39)	1535 (28.22)	79% (77%; 81%); p-value <0.0001
Boosted	4371 (2.79)	50 (0.92)	82% (75%; 87%); p-value <0.0001

\* VE was adjusted for age, sex, and time between outcome occurrence and pandemic initiation.

comorbid patients importantly increments the protection against SARS-CoV-2 infection. The increase in protection was the most noticeable in boosted patients with major health problems like cancer (from 54% to 81%) and obesity (from 67% to 91%) as compared to non-boosted patients. VE against severe COVID-19 (hospitalization, ICU admission or death) was assessed in the mixed population of non-boosted and boosted

**Table 3**  
Vaccine effectiveness (VE) against COVID-19-related hospitalization.

Covid-19 vaccination	Hospitalization		
	No N (%)	Yes N (%)	VE* (95%CI); p-value
<b>≥ 11 years</b>			
Unvaccinated	64,251 (73.59)	4609 (78.50)	Reference
Partially vaccinated	8459 (9.69)	431 (7.34)	42% (35%; 48%); p-value <0.0001
Non-boosted/boosted	14,598 (16.72)	831 (14.15)	72% (68%; 75%); p-value <0.0001
<b>11–17 years</b>			
Unvaccinated	9945 (92.65)	45 (97.83)	Reference
Partially vaccinated	704 (6.56)	1 (2.17)	NA
Non-boosted/boosted	85 (0.79)	0 (0.00)	NA
<b>18–30 years</b>			
Unvaccinated	18,462 (83.91)	283 (88.44)	Reference
Partially vaccinated	2468 (11.22)	30 (9.38)	29% (–5%; 51%); p-value = 0.086
Non-boosted/boosted	1072 (4.87)	7 (2.19)	69% (29%; 87%); p-value = 0.006
<b>31–45 years</b>			
Unvaccinated	14,424 (70.08)	601 (84.53)	Reference
Partially vaccinated	2848 (13.84)	69 (9.70)	58% (45%; 68%); p-value <0.0001
Non-boosted/boosted	3311 (16.09)	41 (5.77)	76% (66%; 83%); p-value <0.0001
<b>46–55 years</b>			
Unvaccinated	8666 (65.13)	670 (85.68)	Reference
Partially vaccinated	681 (5.12)	35 (4.48)	46% (22%; 63%); p-value = 0.001
Non-boosted/boosted	3959 (29.75)	77 (9.85)	84% (78%; 88%); p-value <0.0001
<b>56–65 years</b>			
Unvaccinated	5888 (63.85)	769 (81.20)	Reference
Partially vaccinated	788 (8.54)	69 (7.29)	45% (27%; 59%); p-value <0.0001
Non-boosted/boosted	2546 (27.61)	109 (11.51)	76% (68%; 83%); p-value <0.0001
<b>66–80 years</b>			
Unvaccinated	4828 (62.26)	1298 (78.24)	Reference
Partially vaccinated	492 (6.34)	105 (6.33)	29% (11%; 44%); p-value = 0.004
Non-boosted/boosted	2435 (31.40)	256 (15.43)	71% (62%; 78%); p-value <0.0001
<b>≥ 81 years</b>			
Unvaccinated	2038 (54.99)	943 (67.07)	Reference
Partially vaccinated	478 (12.90)	122 (8.68)	48% (35%; 59%); p-value <0.0001
Non-boosted/boosted	1190 (32.11)	341 (24.25)	73% (64%; 80%); p-value <0.0001

\* : VE was adjusted for age, sex, and time between outcome occurrence and pandemic initiation. NA: VE estimation is not applicable due to a lack of observations.

people. The odds of COVID-19 related hospitalization decreased between 49% and 79% after vaccinating comorbid patients. Important VE against COVID-19-related ICU admission (>80%) was seen in patients with cancer, depression, diabetes, hypertension, or obesity. Considering the deficit of studies that evaluated COVID-19 VE in subpopulations of comorbid patients, the findings of the present study could prove useful for future systematic reviews and meta-analyses.

The main strength of our study lies in its population-based nature where all individuals vaccinated in Galicia-Spain during the study period were assessed for their inclusion in the study; thus, selection bias is only remotely probable. Exposure misclassification is also improbable to have occurred as in Galicia-Spain, all population had access to free of charge COVID-19 vaccine. Vaccination was managed by the regional health care organism and corresponding data were electronically

**Table 4**  
Vaccine effectiveness (VE) against SARS-CoV-2 infection and COVID-19 hospitalization stratified by comorbidity.

Covid-19 vaccination	Infection		
	No N (%)	Yes N (%)	VE* (95%CI); p-value
<b>Obesity</b>			
Unvaccinated	127,335 (53.89)	9223 (72.41)	Reference
Partially vaccinated	25,207 (10.67)	1077 (8.46)	41% (37%; 45%); p-value <0.0001
Non-boosted	81,711 (34.58)	2426 (19.05)	67% (65%; 69%); p-value <0.0001
Boosted	2033 (0.86)	11 (0.09)	91% (83%; 95%); p-value <0.0001
<b>Depression</b>			
Unvaccinated	99,231 (48.55)	5383 (65.09)	Reference
Partially vaccinated	22,995 (11.24)	811 (9.81)	36% (30%; 41%); p-value <0.0001
Non-boosted	79,917 (39.06)	2056 (24.86)	62% (59%; 65%); p-value <0.0001
Boosted	2344 (1.15)	20 (0.24)	83% (74%; 89%); p-value <0.0001
<b>Diabetes</b>			
Unvaccinated	73,600 (43.58)	4681 (65.79)	Reference
Partially vaccinated	19,514 (11.56)	597 (8.39)	44% (38%; 49%); p-value <0.0001
Non-boosted	73,354 (43.44)	1819 (25.57)	65% (62%; 68%); p-value <0.0001
Boosted	2400 (1.42)	18 (0.25)	84% (75%; 90%); p-value <0.0001
<b>COPD</b>			
Unvaccinated	31,329 (41.47)	1532 (64.75)	Reference
Partially vaccinated	8278 (10.96)	161 (6.80)	48% (38%; 56%); p-value <0.0001
Non-boosted	34,691 (45.92)	666 (28.15)	61% (55%; 67%); p-value <0.0001
Boosted	1241 (1.64)	7 (0.30)	84% (66%; 93%); p-value <0.0001
<b>Atrial fibrillation</b>			
Unvaccinated	33,498 (37.29)	1882 (64.76)	Reference
Partially vaccinated	10,004 (11.14)	228 (7.85)	43% (35%; 51%); p-value <0.0001
Non-boosted	44,643 (49.69)	781 (26.88)	64% (58%; 69%); p-value <0.0001
Boosted	1693 (1.88)	15 (0.52)	73% (54%; 85%); p-value <0.0001
<b>Hypertension</b>			
Unvaccinated	169,915 (43.48)	10,930 (65.56)	Reference
Partially vaccinated	44,592 (11.41)	1341 (8.04)	45% (41%; 48%); p-value <0.0001
Non-boosted	170,803 (43.70)	4348 (26.08)	65% (63%; 68%); p-value <0.0001
Boosted	5502 (1.41)	53 (0.32)	82% (76%; 86%); p-value <0.0001
<b>Cardiac failure</b>			
Unvaccinated	30,688 (37.72)	1441 (65.77)	Reference
Partially vaccinated	9201 (11.31)	210 (9.58)	33% (22%; 43%); p-value <0.0001
Non-boosted	39,902 (49.05)	530 (24.19)	70% (64%; 75%); p-value <0.0001
Boosted	1558 (1.92)	10 (0.46)	80% (61%; 90%); p-value <0.0001
<b>Kidney failure</b>			
Unvaccinated	30,755 (38.47)	1411 (64.58)	Reference
Partially vaccinated	9021 (11.28)	183 (8.38)	39% (28%; 48%); p-value <0.0001
Non-boosted	38,152 (47.72)	581 (26.59)	67% (61%; 72%); p-value <0.0001
Boosted	2027 (2.54)	10 (0.46)	85% (70%; 92%); p-value <0.0001

**Table 4 (continued)**

Covid-19 vaccination	Infection		
	No N (%)	Yes N (%)	VE* (95%CI); p-value
<b>Cancer</b>			
Unvaccinated	73,865 (46.18)	3445 (65.14)	Reference
Partially vaccinated	18,558 (11.60)	426 (8.05)	35% (28%; 48%); p-value <0.0001
Non-boosted	65,200 (40.77)	1403 (26.53)	54% (49%; 59%); p-value <0.0001
Boosted	2317 (1.45)	15 (0.28)	81% (68%; 88%); p-value <0.0001
<b>Ischemic heart disease</b>			
Unvaccinated	30,813 (42.15)	1686 (65.22)	Reference
Partially vaccinated	8202 (11.22)	193 (7.47)	38% (27%; 47%); p-value <0.0001
Non-boosted	32,960 (45.09)	697 (26.96)	56% (49%; 63%); p-value <0.0001
Boosted	1125 (1.54)	9 (0.35)	79% (60%; 90%); p-value <0.0001
<b>Stroke</b>			
Unvaccinated	25,764 (39.14)	1328 (64.00)	Reference
Partially vaccinated	7782 (11.82)	243 (11.71)	29% (18%; 38%); p-value <0.0001
Non-boosted	31,093 (47.23)	496 (23.90)	66% (60%; 71%); p-value <0.0001
Boosted	1194 (1.81)	8 (0.39)	85% (68%; 93%); p-value <0.0001
<b>Epilepsy</b>			
Unvaccinated	11,238 (47.73)	653 (67.81)	Reference
Partially vaccinated	2794 (11.87)	123 (12.77)	26% (9%; 40%); p-value = 0.004
Non-boosted/boosted	9512 (40.40)	187 (19.42)	66% (58%; 73%); p-value <0.0001
<b>Dementia</b>			
Unvaccinated	15,244 (27.52)	1047 (56.32)	Reference
Partially vaccinated	7621 (13.76)	320 (17.21)	38% (29%; 45%); p-value <0.0001
Non-boosted	31,054 (56.07)	477 (25.66)	81% (77%; 84%); p-value <0.0001
Boosted	1464 (2.64)	15 (0.81)	88% (78%; 90%); p-value <0.0001
<b>Parkinson</b>			
Unvaccinated	4790 (31.90)	275 (59.40)	Reference
Partially vaccinated	2011 (13.39)	70 (15.12)	35% (15%; 50%); p-value = 0.002
Non-boosted/boosted	8216 (54.71)	118 (25.49)	74% (64%; 81%); p-value <0.0001
<b>HIV</b>			
Unvaccinated	2350 (54.16)	90 (62.94)	Reference
Partially vaccinated	531 (12.24)	10 (6.99)	35% (-30%; 67%); p-value = 0.229
Non-boosted/boosted	1458 (33.60)	43 (30.07)	30% (-16%; 57%); p-value = 0.166

COPD: chronic obstructive pulmonary disease. HIV: human immunodeficiency virus.

\* : VE was adjusted for sex, age, and time between outcome occurrence and pandemic initiation.

registered. The estimated VE was adjusted for a wide range of possible confounding variables including socio-demographic, socioeconomic, and clinical variables. The extent of exposure to SARS-CoV-2 varies across settings which if present would bias VE estimates, and residual confounding from unmeasured factors such as health seeking behavior, application of different non-pharmaceutical measures during the study period and adherence to the use of facemasks might have still been present. The outcomes, SARS-CoV-2 infection and disease severity, in our study were ascertained through clinical and medical based records, yet the possibility of outcome misclassification from a false positive or a false negative test result or from inaccurate diagnosis codes cannot be



**Table 5**  
Vaccine effectiveness (VE) against COVID-19 hospitalization stratified by comorbidity.

Covid-19 vaccination	Hospitalization		
	No N (%)	Yes N (%)	VE* (95%CI); p-value
<b>Obesity</b>			
Unvaccinated	7436 (70.72)	1459 (79.77)	Reference
Partially vaccinated	929 (8.83)	135 (7.38)	43% (30%; 54%); p-value <0.0001
Non-boosted/boosted	2150 (20.45)	235 (12.85)	78% (73%; 83%); p-value <0.0001
<b>Depression</b>			
Unvaccinated	4303 (62.92)	856 (74.05)	Reference
Partially vaccinated	713 (10.43)	88 (7.61)	52% (38%; 63%); p-value <0.0001
Non-boosted/boosted	1823 (26.66)	212 (18.34)	69% (59%; 77%); p-value <0.0001
<b>Diabetes</b>			
Unvaccinated	3267 (61.95)	1124 (75.54)	Reference
Partially vaccinated	476 (9.03)	108 (7.26)	48% (34%; 59%); p-value <0.0001
Non-boosted/boosted	1531 (29.03)	256 (17.20)	74% (65%; 80%); p-value <0.0001
<b>COPD</b>			
Unvaccinated	931 (59.60)	461 (72.37)	Reference
Partially vaccinated	122 (7.81)	35 (5.49)	43% (14%; 63%); p-value = 0.008
Non-boosted/boosted	509 (32.59)	141 (22.14)	71% (51%; 82%); p-value <0.0001
<b>Atrial fibrillation</b>			
Unvaccinated	1076 (58.96)	592 (71.58)	Reference
Partially vaccinated	161 (8.82)	57 (6.89)	42% (19%; 58%); p-value = 0.001
Non-boosted/boosted	588 (32.22)	178 (21.52)	68% (51%; 79%); p-value <0.0001
<b>Hypertension</b>			
Unvaccinated	8074 (62.30)	2247 (75.40)	Reference
Partially vaccinated	1110 (8.57)	209 (7.01)	47% (37%; 55%); p-value <0.0001
Non-boosted/boosted	3775 (29.13)	524 (17.58)	73% (67%; 78%); p-value <0.0001
<b>Cardiac failure</b>			
Unvaccinated	682 (58.14)	543 (71.83)	Reference
Partially vaccinated	140 (11.94)	58 (7.67)	52% (33%; 66%); p-value <0.0001
Non-boosted/boosted	351 (29.92)	155 (20.50)	72% (54%; 83%); p-value <0.0001
<b>Kidney failure</b>			
Unvaccinated	716 (57.42)	519 (71.29)	Reference
Partially vaccinated	137 (10.99)	39 (5.36)	66% (50%; 77%); p-value <0.0001
Non-boosted/boosted	394 (31.60)	170 (23.35)	78% (60%; 88%); p-value <0.0001
<b>Cancer</b>			
Unvaccinated	2545 (61.77)	666 (74.41)	Reference
Partially vaccinated	364 (8.83)	56 (6.26)	45% (25%; 60%); p-value <0.0001
Non-boosted/boosted	1211 (29.39)	173 (19.33)	66% (50%; 82%); p-value <0.0001
<b>Ischemic heart disease</b>			
Unvaccinated	1094 (61.29)	443 (71.80)	Reference
Partially vaccinated	145 (8.12)	40 (6.48)	39% (10%; 58%); p-value = 0.014
Non-boosted/boosted	546 (30.59)	134 (21.72)	49% (19%; 67%); p-value = 0.004
<b>Stroke</b>			
Unvaccinated	848 (59.26)	357 (72.41)	Reference
Partially vaccinated	191 (13.35)	42 (8.52)	55% (35%; 69%); p-value <0.0001
	392 (27.39)	94 (19.07)	

**Table 5 (continued)**

Covid-19 vaccination	Hospitalization		
	No N (%)	Yes N (%)	VE* (95%CI); p-value
Non-boosted/boosted			70% (49%; 83%); p-value <0.0001
<b>Epilepsy</b>			
Unvaccinated	518 (66.58)	103 (73.05)	Reference
Partially vaccinated	100 (12.85)	20 (14.18)	8% (-62%; 47%); p-value = 0.785
Non-boosted/boosted	160 (20.57)	18 (12.77)	32% (-55%; 71%); p-value = 0.355
<b>Dementia</b>			
Unvaccinated	634 (50.72)	322 (65.71)	Reference
Partially vaccinated	251 (20.08)	64 (13.06)	48% (29%; 62%); p-value <0.0001
Non-boosted/boosted	365 (29.20)	104 (21.22)	79% (62%; 89%); p-value <0.0001
<b>Parkinson</b>			
Unvaccinated	149 (51.56)	96 (72.73)	Reference
Partially vaccinated	61 (21.11)	8 (6.06)	80% (60%; 91%); p-value <0.0001
Non-boosted/boosted	79 (27.34)	28 (21.21)	73% (-4%; 93%); p-value = 0.058
<b>HIV</b>			
Unvaccinated	79 (62.20)	9 (64.29)	Reference
Partially vaccinated	9 (7.09)	1 (7.14)	NA
Non-boosted/boosted	39 (30.71)	4 (28.57)	NA

*COPD*: chronic obstructive pulmonary disease. *HIV*: human immunodeficiency virus. *NA*: VE estimation is not applicable due to a lack of observations.

\* : VE was adjusted for sex, age, and time between outcome occurrence and pandemic initiation.

ruled out. If it occurred, this non-differential misclassification could have underestimated the VE. The imperfect sensitivity of PCR testing could cause misclassification, which could attenuate VE estimates (Fonseca et al., 2021). We excluded from the analysis individuals who were infected with SARS-CoV-2 before the study initiation in order to account for acquired immunity from a past infection. Nonetheless, asymptomatic patients are likely not to be tested for SARS-CoV-2 which if present could overestimate our findings on VE. The time passed since booster dose administration until outcome development could influence VE estimates. We did not stratify for this variable due to insufficient observations, however, we controlled the analysis for the time between COVID-19 pandemic initiation and outcome occurrence. Other studies are encouraged to control for time since booster dose administration. Our data lacks information on SARS-CoV-2 variant in positively tested individuals, accordingly VE stratified by SARS-CoV-2 variant is lacking. SARS-CoV-2 variants might affect COVID-19 VE, consequently, a continuous assessment of vaccine performance is needed. Future studies are required to estimate the effectiveness of booster-based schedule on COVID-19 severity in young adults.

## 5. Conclusions

The need for booster dose(s) of COVID-19 vaccines remains an issue of debate. Vaccine performance varies across settings and populations, hence determining the extent and duration of VE using real-world data is crucial to inform related authorities and design specific prevention programs that take into account the vaccination calendar, the need for booster dose/s and the vulnerable populations. Our findings suggest that, in settings like Spain, booster-based vaccine schedule increments the protection against to SARS-CoV-2 infection and COVID-19 severity. Importantly, COVID-19 vaccine booster administration considerably protects patients with major comorbidities.

## Funding

This work was supported by Framework Partnership Agreement between the Consellería de Sanidad de la XUNTA de Galicia and GENVIP-IDIS-2021–2024 (SERGAS-IDIS March 2021; Spain); and consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; F.M-T), DIAVIR (Instituto de Salud Carlos III (ISCIII)/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III (ISCIII)/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud (ACIS)—Servicio Gallego de Salud (SERGAS)—Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACIS—Servicio Gallego de Salud (SERGAS)—XUNTA de Galicia; Spain) and Axencia Galega de Innovación (GAIN; IN607B 2020/08—XUNTA de Galicia; Spain) [A.S]; and ReSVinext (Instituto de Salud Carlos III (ISCIII)/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III (ISCIII)/PI19/01090/Cofinanciado FEDER), and Axencia Galega de Innovación (GAIN; IN845D 2020/23—Xunta de Galicia; Spain) [F.M-T].

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Data availability

Data will be made available on request.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.envres.2022.114252>.

## References

- Adab, P., Haroon, S., O'Hara, M.E., Jordan, R.E., 2022. Comorbidities and covid-19. *BMJ* 377, o1431.
- Andrews, N., Stowe, J., Kirsebom, F., et al., 2022. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. *Nat. Med.* 28 (4), 831–837.
- Arbel, R., Hammerman, A., Sergienko, R., et al., 2021. BNT162b2 vaccine booster and mortality due to covid-19. *N. Engl. J. Med.* 385 (26), 2413–2420.
- Bar-On, Y.M., Goldberg, Y., Mandel, M., et al., 2021. Protection of BNT162b2 vaccine booster against covid-19 in Israel. *N. Engl. J. Med.* 385 (15), 1393–1400.
- Barda, N., Dagan, N., Cohen, C., et al., 2021. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet* 398 (10316), 2093–2100.
- CDC: Center for Disease Control and Prevention. COVID-19, people with certain medical conditions. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>. (Accessed 24 March 2022). Accessed.
- Chiner-Vives, E., Cordovilla-Perez, R., de la Rosa-Carrillo, D., et al., 2022. Short and long-term impact of COVID-19 infection on previous respiratory diseases. *Arch. Bronconeumol.* 58 (Suppl. 1), 39–50.
- Ejaz, H., Alsrhani, A., Zafar, A., et al., 2020. COVID-19 and comorbidities: deleterious impact on infected patients. *J Infect Public Health* 13 (12), 1833–1839.
- European Medicines Agency. COVID-19 vaccines: authorised. Available at: <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised>. Accessed June 01, 2022.
- Feikin, D.R., Higdon, M.M., Abu-Raddad, L.J., et al., 2022. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 399 (10328), 924–944.
- Florea, A., Sy, L.S., Luo, Y., et al., 2022. Durability of mRNA-1273 against COVID-19 in the time of Delta: interim results from an observational cohort study. *PLoS One* 17 (4), e0267824.
- Fonseca, E., Ferreira, L.C., Loureiro, B.M.C., et al., 2021. Chest computed tomography in the diagnosis of COVID-19 in patients with false negative RT-PCR. *Einstein (Sao Paulo)* 19, eAO6363.
- Gobierno de España [Spanish Government]. Estrategia de vacunación COVID-19 [COVID-19 vaccination strategy]. Available at: <https://www.vacunacovid.gob.es>. Accessed June 012022.
- Gonzalez-Barcala, F.J., Nieto-Fontarigo, J.J., Mendez-Brea, P., Salgado, F.J., 2022. The polyhedral reality of the interaction between COVID-19, asthma and inhaled corticosteroids. *ERJ Open Res* 8 (2).
- Greenland, S., 1989. Modeling and variable selection in epidemiologic analysis. *Am. J. Publ. Health* 79 (3), 340–349.
- He, Z.F., Zhong, N.S., Guan, W.J., 2022. Impact of chronic respiratory diseases on the outcomes of COVID-19. *Arch. Bronconeumol.* 58 (1), 5–7.
- Instituto Galego de Estatística [Galician Statistical Office], 2019. <https://www.ige.eu/ige/bdt/esqv.jsp?ruta=verTabla.jsp?OP=1&B=1&M=&COD=77&R=9915>. (Accessed 29 November 2021).
- Instituto Galego de Estatística [Galician Statistical Office], 2020. Hospitais [hospitals] [12];1 & C=0[all]&F=&S=&SCF= Accessed. <https://www.ige.eu/ige/bdt/esqv.jsp?ruta=verTabla.jsp?OP=1&B=1&M=&COD=2922&R=9915>. (Accessed 29 November 2021). Accessed.
- Instituto Galego de Estatística [Galician Statistical Office], 2021. Población [population]. Available at: <http://www.ige.eu/web/index.jsp?idioma=gl>. (Accessed 29 November 2021).
- Instituto Galego de Estatística [Galician Statistical Office], 2021. Poboación por sexo e grupos quinquenais de idade. Ano 2021 [Population by sex and five-year age groups. Year 2021]. Available at: <https://www.ige.eu/ige/bdt/esqv.jsp?paxina=002001&c=0201001002&ruta=verPpalesResultados.jsp?OP=1&B=1&M=&COD=1373&R=2%5Ball%5D&C=1%5Ball%5D&F=T>. (Accessed 29 November 2021).
- Jara, A., Undurraga, E.A., Zubizarreta, J.R., et al., 2022. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. *Lancet Global Health* 10 (6), E798–E806.
- Khoury, J., Najjar-Debbiny, R., Hanna, A., et al., 2021. COVID-19 vaccine - long term immune decline and breakthrough infections. *Vaccine* 39 (48), 6984–6989.
- Mehta, H.B., Li, S., Goodwin, J.S., 2021. Risk factors associated with SARS-CoV-2 infections, hospitalization, and mortality among US nursing home residents. *JAMA Netw. Open* 4 (3), e216315.
- Ministerio de Sanidad Consumo y Bienestar Social [Ministry of Health Consumption and Social Welfare]. Informe nº 106. Situación de COVID-19 en España 24 de noviembre de 2021 [Report nº 106. COVID-19 situation in Spain. November 24]. Available at: <https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/-COVID-19.-Informes-previos.aspx>. Accessed June 01 2021 2022.
- Monge, S., Rojas-Benedicto, A., Olmedo, C., et al., 2022. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. *Lancet Infect. Dis.* 22 (9), 1313–1320.
- Naaber, P., Tserel, L., Kangro, K., et al., 2021. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. *Lancet Reg Health Eur* 10, 100208.
- Pardo-Seco, J., Mallah, N., Lopez-Perez, L.R., et al., 2022. Evaluation of BNT162b2 vaccine effectiveness in Galicia, northwest Spain. *Int. J. Environ. Res. Publ. Health* 19 (7).
- Patalon, T., Gazit, S., Pitzer, V.E., Prunas, O., Warren, J.L., Weinberger, D.M., 2022. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. *JAMA Intern. Med.* 182 (2), 179–184.
- Shekhar, R., Garg, I., Pal, S., Kottewar, S., Sheikh, A.B., 2021. COVID-19 vaccine booster: to boost or not to boost. *Infect. Dis. Rep.* 13 (4), 924–929.
- Thompson, M.G., Natarajan, K., Irving, S.A., et al., 2022. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 States, august 2021-january 2022. *MMWR Morb. Mortal. Wkly. Rep.* 71 (4), 139–145.
- Tut, G., Lancaster, T., Krutikov, M., et al., 2021. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. *Lancet Healthy Longev* 2 (9), e544–e553.
- World Health Organization. Interim statement on booster doses for COVID-19 vaccination. Available at: <https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination-update-22-december-2021>. (Accessed 24 March 2022). Accessed.
- Yeo, I., Baek, S., Kim, J., et al., 2021. Assessment of thirty-day readmission rate, timing, causes and predictors after hospitalization with COVID-19. *J. Intern. Med.* 290 (1), 157–165.